Roland Baron is a Professor at Harvard Medical School and Head of the Division of Bone and Mineral Research at the Harvard School of Dental Medicine. Prior to joining Harvard, Baron held a Professorship in the departments of Medicine, Orthopedics, and Cell Biology at Yale University School of Medicine.
Baron held the position of Vice President and Head of the Bone Diseases Group at Hoechst Marion Roussel and later at Aventis Pharma. In 2002, he founded ProSkelia, a small pharmaceutical company devoted to the discovery and development of new drugs for bone and hormonal-dependent diseases, which is now part of Galapagos. Baron held the positions of President and Chief Scientific Officer of ProSkelia and then ProStrakan, until April 2006.
He currently serves as the co-Chair of the International Federation of Musculoskeletal Research Societies (IFMRS). Previously, he served as President of the European Calcified Tissue Society, and as President of the American Society for Bone and Mineral Research (ASBMR).
He received his DDS and PhD degrees from the Medical School, University of Paris, France. Additionally, he is the founder and past Editor-in-Chief of BONE, a prominent research journal in the field. Baron has received several awards, including the Doctor Honoris Causa of the Université René Descartes (2002, Paris, France), the MERIT Award from the NIH, NIDCR, the William Neuman Award (2009) and the Avioli Founder Award (2002) from ASBMR, the Harold Copp Award from the International Bone and Mineral Society (2005, IBMS), and the Excellence in Research Award from the European Calcified Tissue Society (2014, ECTS). He has published over 390 scientific papers in the field of bone biology, bone diseases, and their treatment.
